文献速递前列腺增生与排尿功能障碍

维生素D补充对老年男性膀胱过度活动症与尿失禁症状的影响:一项随机试验的辅助研究结果

Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial.
PubMed 文献 · J Urol · 2022-09-06

该研究为VITAL随机试验的辅助分析,纳入≥55岁男性,比较维生素D3与安慰剂对膀胱过度活动症和尿失禁的影响。整体上维生素D补充未降低膀胱过度活动症或尿失禁的 odds;基线25-羟基维生素D<20 ng/mL者中,维生素D组膀胱过度活动症 odds 较低但任何尿失禁 odds 较高,结果不一致。

要点

  • 整体分析中维生素D补充未降低第5年膀胱过度活动症 odds(OR 0.97,95%CI 0.87-1.08)。
  • 整体分析中维生素D补充未降低第2年或第5年每周尿失禁 odds。
  • 基线25-羟基维生素D<20 ng/mL者中,维生素D组膀胱过度活动症 odds 较低但任何尿失禁 odds 较高,结果不一致。

核心结论

  • 整体上,与安慰剂相比,维生素D补充未改善膀胱过度活动症或尿失禁。
  • 在基线25-羟基维生素D水平较低的男性中,维生素D的使用结果不一致。

研究设计与样本

  • VITAL(VITamin D and OmegA-3 TriaL)随机试验的辅助研究,纳入年龄≥55岁男性。
  • 随机治疗包括维生素D3(胆钙化醇)、海洋ω-3脂肪酸或匹配安慰剂。
  • 第2年有11,486名男性提供数据,第5年有10,474名男性提供数据;第2年时平均年龄68岁,23%为种族/族裔少数群体。

主要发现

  • 与安慰剂相比,维生素D补充未降低第5年膀胱过度活动症的 odds(OR 0.97,95% CI 0.87-1.08)。
  • 与安慰剂相比,维生素D补充未降低第2年每周尿失禁的 odds(OR 0.94,95% CI 0.83-1.05)。
  • 与安慰剂相比,维生素D补充未降低第5年每周尿失禁的 odds(OR 0.98,95% CI 0.88-1.09)。
  • 基线血清25-羟基维生素D水平与维生素D补充对膀胱过度活动症存在交互作用(交互作用 P 值 = .001)。
  • 基线血清25-羟基维生素D水平与维生素D补充对第2年任何尿失禁存在交互作用(交互作用 P 值 = .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to evaluate vitamin D supplementation for preventing or treating overactive bladder and urinary incontinence in men. MATERIALS AND METHODS: Ancillary study of men aged ≥55 years in VITAL (VITamin D and OmegA-3 TriaL). Randomized treatments included: vitamin D3 (cholecalciferol), marine omega-3 fatty acids, or matching placebo. Structured urinary incontinence questions measured the prevalence of overactive bladder at year 5 and urinary incontinence at years 2 and 5, along with incidence and progression of urinary incontinence from years 2 to 5. Prespecified subgroup analyses examined men with low baseline serum 25-hydroxyvitamin D (<20 ng/mL). RESULTS: Among the 11,486 men who provided data at year 2 and 10,474 at year 5, mean age was 68 years at year 2, with 23% racial/ethnic minorities. In primary analyses, vitamin D supplementation compared to placebo did not lower odds of overactive bladder at year 5 (OR 0.97, 95% CI 0.87-1.08) or weekly urinary incontinence at year 2 (OR 0.94, 95% CI 0.83-1.05) or year 5 (OR 0.98, 95% CI 0.88-1.09). We found interactions of baseline serum 25-hydroxyvitamin D level with vitamin D supplementation for overactive bladder (P value for interaction = .001), and secondarily, for any urinary incontinence at year 2 (P value for interaction = .05). Men with baseline 25-hydroxyvitamin D <20 ng/mL, who were assigned to vitamin D supplements, had lower odds of overactive bladder (OR 0.51, 95% CI 0.35-0.76) compared to placebo, yet higher odds of any urinary incontinence (OR 1.24, 95% CI 0.93-1.64). CONCLUSIONS: Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Markland AD, Vaughan CP, Huang AJ, et al. Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial. J Urol. 2022. PMID: 36067369. doi:10.1097/JU.0000000000002942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。